

Richard Kones

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/221286/publications.pdf>

Version: 2024-02-01

21
papers

651
citations

759233

12
h-index

713466

21
g-index

22
all docs

22
docs citations

22
times ranked

1018
citing authors

#	ARTICLE	IF	CITATIONS
1	Lipoprotein(a): Current Evidence for a Physiologic Role and the Effects of Nutraceutical Strategies. <i>Clinical Therapeutics</i> , 2019, 41, 1780-1797.	2.5	35
2	Cardiac rehabilitation underutilization: Missed opportunities in comprehensive cardiac care. <i>International Journal of Cardiology</i> , 2019, 292, 39-40.	1.7	3
3	A General Pathway Model for Improving Health Disparities: Lessons from Community and Cultural Involvement in Improving Cervical Cancer Screening in Vietnamese Women. <i>Journal of Clinical Medicine</i> , 2019, 8, 154.	2.4	1
4	Trends in Guideline-Driven Revascularization in Diabetic Patients with Multivessel Coronary Heart Disease. <i>Journal of Cardiovascular Development and Disease</i> , 2019, 6, 41.	1.6	4
5	Confronting the most challenging risk factor: non-adherence. <i>Lancet, The</i> , 2019, 393, 105-106.	13.7	17
6	Cultural primer for cardiometabolic health: health disparities, structural factors, community, pathways to improvement, and clinical applications. <i>Postgraduate Medicine</i> , 2018, 130, 200-221.	2.0	7
7	Barriers to Global Action Plan for the Prevention and Control of Noncommunicable Diseases: Proposal Modifications to the Voluntary Targets. <i>Journal of Preventive Medicine</i> , 2018, 03, .	0.4	7
8	Cardiometabolic diseases of civilization: history and maturation of an evolving global threat. An update and call to action. <i>Annals of Medicine</i> , 2017, 49, 260-274.	3.8	29
9	n-3 Polyunsaturated Fatty Acids and Cardiovascular Disease: Principles, Practices, Pitfalls, and Promises - A Contemporary Review. <i>Medical Principles and Practice</i> , 2017, 26, 497-508.	2.4	25
10	Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs. <i>Drugs</i> , 2015, 75, 1201-1228.	10.9	18
11	Current Treatment of Dyslipidemia: A New Paradigm for Statin Drug Use and the Need for Additional Therapies. <i>Drugs</i> , 2015, 75, 1187-1199.	10.9	24
12	Cardiovascular Prevention: Components, Levels, Early Origins, and Metrics. <i>Hospital Practice (1995)</i> , 2014, 42, 84-95.	1.0	5
13	Exclusion of "nonRCT evidence"™ in guidelines for chronic diseases " is it always appropriate? The Look AHEAD study. <i>Current Medical Research and Opinion</i> , 2014, 30, 2009-2019.	1.9	12
14	Increasing long-chain n-3PUFA consumption improves small peripheral artery function in patients at intermediate"high cardiovascular risk. <i>Journal of Nutritional Biochemistry</i> , 2014, 25, 642-646.	4.2	19
15	Dyslipidemia, Risk Factors, and the Prevention of Cardiovascular Disease in Women. <i>Journal of Women's Health</i> , 2013, 22, 402-403.	3.3	1
16	Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. <i>Vascular Health and Risk Management</i> , 2013, 9, 617.	2.3	71
17	Is prevention a fantasy, or the future of medicine? A panoramic view of recent data, status, and direction in cardiovascular prevention. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2011, 5, 61-81.	2.1	37
18	Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. <i>Drug Design, Development and Therapy</i> , 2011, 5, 325.	4.3	201

#	ARTICLE	IF	CITATIONS
19	Inflammation, C-reactive protein and cardiometabolic risk: how compelling is the potential therapeutic role of n-3 PUFAs in cardiovascular disease?. <i>Clinical Lipidology</i> , 2011, 6, 627-630.	0.4	1
20	Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease – a perspective. <i>Drug Design, Development and Therapy</i> , 2010, 4, 383.	4.3	91
21	Recent advances in the management of chronic stable angina I: Approach to the patient, diagnosis, pathophysiology, risk stratification, and gender disparities. <i>Vascular Health and Risk Management</i> , 2010, 6, 635.	2.3	43